ABSTRACT
This case series reports six patients (four men and two women; median age, 38 years; interquartile range, 26-48 years) who presented with vaccine-induced thrombocytopenia and thrombosis beginning 3-26 days after receiving the first dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine for COVID-19. The patients were admitted to a general hospital between 9 and 31 days after the first dose. All patients had strongly detected antiplatelet factor 4 antibodies and severe thrombosis. Laboratory features included thrombocytopenia and elevated d-dimer levels. Thrombotic events were predominantly venous; two patients had arterial or mixed arterial and venous thrombosis. All patients recovered after receiving intravenous immunoglobulin and nonheparin-based anticoagulation. © RSNA, 2021 An earlier incorrect version appeared online. This article was corrected on August 18, 2021.
Subject(s)
ChAdOx1 nCoV-19/adverse effects , Diagnostic Imaging/methods , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnostic imaging , Venous Thrombosis/chemically induced , Venous Thrombosis/diagnostic imaging , Adult , Anticoagulants/therapeutic use , COVID-19/prevention & control , Female , Fibrin Fibrinogen Degradation Products , Humans , Immunoglobulins, Intravenous/therapeutic use , Lung/diagnostic imaging , Male , Middle Aged , Retrospective Studies , SARS-CoV-2 , Thrombocytopenia/drug therapy , Venous Thrombosis/drug therapyABSTRACT
The relationship between serum paraprotein and beta2-microglobulin (B2m) levels was studied in serial samples from 41 patients with myeloma. A positive correlation coefficient was found in 70.7% of myeloma patients indicating that no extra information was gained from measuring both analytes routinely. As a result, the workload for B2m fell without any diminution in clinical service.
